贵州苗药生物技术有限公司生产车间里同样忙碌，员工正赶制订单。公司聚焦苗药提取与健康产品研 发，拥有18项专利，产品畅销国内外。2025年总销售额突破1700万元，同比增长50%，海外市场增长迅 速。 江口县森林覆盖率高，气候适宜，中药材资源丰富。全县将中药材列为主导产业之一，重点发展淫羊 藿、黄精等品种，种植规模达5.15万亩。当地正推进中药材GAP建设，加强全程规范，并计划建设科创 中心，延伸产业链。 在江口谷润药业，工人正加紧完成淫羊藿干品的装车发货。该公司与国药同济堂合作，推行订单化生 产，对全县淫羊藿进行标准化加工，2025年干品销售产值达1200万元。 当下，贵州江口县中药材产业产销两旺，迎来产销高峰。 如今，江口县正推动中药材产业标准化、品牌化发展，让"小药材"成为富民强县的"金招牌"。 来源：铜仁融媒 江口融媒 杨再强 ...

齐鲁晚报.齐鲁壹点陈甜田通讯员蔡国伟 近日，滨州医学院附属医院成功举办黄河三角洲转化医学中心成立大会。滨州市科技局党组书记李宁波、滨州医学院附属医院党委书记王东、滨州中裕食 品有限公司党委书记付蕊出席会议并致辞。滨医附院党委委员、科技处处长李伟主持开幕式。滨州市科学技术局、山东航空学院、滨州职业学院、魏桥国 科高研院、山东省滨州畜牧兽医研究院、滨州市海洋发展研究院以及滨州市相关医疗机构和科技企业的近百名代表参加会议。 李宁波代表市科技局对黄河三角洲转化医学中心的成立表示祝贺，同时也充分肯定了滨医附院的科研积累与创新实践。他指出，中心成立是滨州践行黄河 流域生态保护和高质量发展战略、深化"健康中国"建设的重要举措，标志着我市在推动生物医药产业与临床医学研究融合方面迈出实质性步伐。他希望中 心立足区域特色，聚焦精准医疗与临床需求，产出更多原创成果与可转化技术，为黄河三角洲生物医药与大健康产业高质量发展注入持续动力。 王东在讲话中表示，滨医附院牵头成立黄河三角洲转化医学中心，旨在进一步整合区域内的临床资源、科研力量与产业动能，构建一个开放共享、高效协 同的创新共同体。中心将聚焦重大疾病防治、健康产品研发及临床评价验 ...

2025年12月16日，万宁中国官网发布公告，宣布将于2026年1月15日正式关闭中国内地所有线下门店。 与此同时，其线上官方商城将于2025年12月28日停止运营，天猫、京东等平台的旗舰店则提前至12月26 日停运。 这家自2004年进入内地市场、拥有超过120家门店的健与美产品连锁巨头，最终选择结束其长达二十一 年的内地征程。 二十年征程的终结 一个时代的背影与商业逻辑 实际上，市场分析人士认为，这一决定背后是多重因素共同作用的结果。**内地零售市场竞争日趋激 烈，线上渠道的崛起彻底改变了消费者的购物习惯**，而持续上涨的运营成本也给实体零售带来了巨大 压力。 值得注意的是，万宁并非全面退出中国市场。根据公告，其跨境官方商城（小程序）、万宁跨境天猫旗 舰店、万宁跨境京东旗舰店及万宁跨境拼多多旗舰店将继续提供服务。 这意味着万宁将调整其在内地的业务模式，从直营实体店转向以跨境电商业为主的轻资产运营策略。 后万宁时代的零售变局 消费变迁与模式创新 万宁的撤退并非毫无征兆。回顾其在内地市场的发展轨迹，这家香港最大的健与美产品连锁店始终未能 完全复制其在港澳地区的成功模式。 2004年，万宁带着在香港积累的经验和 ...

12月24日，唯科科技涨1.15%，截至发稿，报77.22元/股，成交2.39亿元，换手率3.79%，总市值96.72亿 元。唯科科技股价已经连续3天上涨，区间累计涨幅8.93%。 资料显示，厦门唯科模塑科技股份有限公司位于福建省厦门火炬高新区(翔安)产业区春光路1152号-1156 号(双号)，成立日期2005年4月4日，上市日期2022年1月11日，公司主营业务涉及从事精密注塑模具、 注塑件以及健康产品的研发、设计、制造和销售业务。主营业务收入构成为：注塑产品47.25%，健康 产品31.33%，精密模具18.24%，其他3.19%。 从唯科科技十大流通股东角度 数据显示，永赢基金旗下1只基金位居唯科科技十大流通股东。永赢先进制造智选混合发起A （018124）三季度新进十大流通股东，持有股数392.73万股，占流通股的比例为4.8%。根据测算，今日 浮盈赚取约345.6万元。连续3天上涨期间浮盈赚取2485.97万元。 永赢先进制造智选混合发起A（018124）基金经理为张璐。 截至发稿，张璐累计任职时间6年147天，现任基金资产总规模229.21亿元，任职期间最佳基金回报 115.94%， 任职期间最 ...

永赢先进制造智选混合发起A（018124）基金经理为张璐。 截至发稿，张璐累计任职时间6年145天，现任基金资产总规模229.21亿元，任职期间最佳基金回报 112.82%， 任职期间最差基金回报-60.31%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 12月22日，唯科科技涨5.08%，截至发稿，报74.49元/股，成交1.69亿元，换手率2.84%，总市值93.30亿 元。 资料显示，厦门唯科模塑科技股份有限公司位于福建省厦门火炬高新区(翔安)产业区春光路1152号-1156 号(双号)，成立日期2005年4月4日，上市日期2022年1月11日，公司主营业务涉及从事精密注塑模具、 注塑件以及健康产品的研发、设计、制造和销售业务。主营业务收入构成为：注塑产品47.25%，健康 产品31.33%，精密模具18.24%，其他3.19%。 从唯科科技十大流通股东角度 数据显示，永赢基金旗下1只基金位居唯科科技十大流通股东。永赢先进制造智选混合发起A ...

更深层次的动力，则源于行业格局的深刻变革。经历前期的快速扩张后，医药零售行业正从"野蛮生长"步入"精耕细作"的整合阶 段。数据显示，尽管实体药店总数一度突破70万家，但市场竞争已趋于白热化，部分经营不善的中小连锁药店开始退出市场。自 2024年第四季度以来，行业门店数量已连续两个季度呈现净减少态势。 展望未来，行业龙头的增长路径已清晰可见，即"内生+外延"双轮驱动。一方面，通过优化产品结构、提升服务质量和运营效率，实 现同店增长的"内生性"动力；另一方面，通过并购整合，吸纳优质门店资源，扩大市场份额的"外延式"扩张。目前，部分行业龙头 的直营门店数量约1万家，占行业总数比例仍低，行业格局变化仍处于早期阶段，集中度提升的主线将长期存在。 【环球网消费综合报道】12月18日，A股医药商业板块强势崛起，领涨两市。截至收盘，板块整体上涨5.73%，华人健康20CM涨 停，漱玉平民上涨20.03%，一心堂、英特集团、塞力医疗、重药控股等多股涨停，板块内呈现普涨格局。 这轮行情的背后，是市场对医药商业行业长期增长逻辑的重新认可。在近期公众健康意识提升的背景下，相关药品及健康产品的市 场需求得到提振，为零售药店等终端渠道带 ...

在数字化转型的深水区，传统企业面临着线下流量枯竭、获客成本高企的双重困境。 而微信视频号凭借 13 亿月活用户的生态红利、"公私域联动" 的闭环优势，正成为传统企业低成本触达用户、重构增长曲线的核心 阵地。 其中，视频号小店作为交易转化的关键载体，已实现 "内容曝光 - 用户互动 - 商品成交 - 私域沉淀" 的全链路打通。 本文将结合最新行业数据与实战案例，为传统企业提供一套可直接落地的视频号小店获客体系。 一、认知先行，视频号小店的三大获客优势 传统企业入局视频号小店，首先要明确其与传统电商、其他短视频平台的核心差异，精准把握生态红利。 图片来 源：自制 1. 社交信任背书，降低获客成本 视频号依托微信社交链，形成了 "好友点赞推荐" 的核心分发机制。用户通过好友分享或点赞进入视频号内容，天然带有信任滤镜， 使得获客成本远低于陌生流量平台。 数据显示，微信 "送礼物" 功能带动的书籍类订单，退货率不足 10%，远低于传统电商平台的 30%-50%。 这种基于社交关系的裂变模式，尤其适合需要长期信任培养的行业，如家装、教育、高端制造业等。 2. 公私域闭环，实现流量沉淀 视频号小店可无缝对接企业微信、公众号 ...

Core Viewpoint - CNO Financial's recent earnings report shows strong performance in Q3 2025, with adjusted EPS beating estimates and revenues exceeding expectations, despite a slight decline in share price over the past month [1][2][16]. Financial Performance - CNO Financial reported Q3 2025 adjusted EPS of 96 cents, surpassing the Zacks Consensus Estimate by 1.1%, and an increase from 92 cents a year ago [2]. - Operating revenues reached $1.2 billion, reflecting a year-over-year growth of 5.3% and exceeding the consensus mark by 26.3% [2]. - Total insurance policy income rose 2.1% year over year to $658.4 million, beating the Zacks Consensus Estimate of $653 million [4]. Premiums and Revenues - Collected premiums from annuity, life, and health products contributed to the revenue growth, with total collected premiums increasing 2.1% year over year to $1.1 billion [6]. - Annuity collected premiums improved 1.6% to $472.5 million, health collected premiums rose 2.4% to $412.6 million, and life product premiums increased 2.5% to $247 million [6]. Expenses and Losses - Total benefits and expenses escalated 3% year over year to $1.2 billion, influenced by higher operating costs [7]. - Net investment losses were reported at $8.8 million, a slight improvement from the previous year's loss of $11.1 million [5]. Financial Position - As of September 30, 2025, CNO Financial had unrestricted cash and cash equivalents of $1.2 billion, down 26.5% from the end of 2024 [8]. - Total assets increased by 1.2% to $38.3 billion, while total shareholders' equity grew 3.8% to $2.6 billion [8]. Shareholder Returns - The company returned $60 million to shareholders through share buybacks and $16.4 million in dividends during Q3 [11]. - CNO Financial has a remaining repurchase capacity of $480.4 million as of September 30, 2025 [11]. Guidance and Estimates - CNO Financial revised its operating EPS guidance for 2025 to a range of $3.75-$3.85, up from the previous range of $3.70-$3.90 [12]. - The company now anticipates excess cash flow of $365-$385 million, an increase from the earlier estimate of $200-$250 million [12]. Industry Context - CNO Financial is part of the Zacks Insurance - Multi line industry, where competitor Prudential reported a revenue decline of 16.6% year over year [17]. - Prudential's EPS for the same period was $4.26, compared to $3.48 a year ago, indicating a different performance trajectory within the industry [17].

Group 1 - The core point of the news is that Weike Technology's stock has dropped by 5.06%, with a current price of 74.91 CNY per share and a total market capitalization of 9.383 billion CNY [1] - Weike Technology, established on April 4, 2005, and listed on January 11, 2022, is primarily engaged in the research, design, manufacturing, and sales of precision injection molds, injection products, and health products [1] - The revenue composition of Weike Technology includes injection products at 47.25%, health products at 31.33%, precision molds at 18.24%, and others at 3.19% [1] Group 2 - Among the top circulating shareholders of Weike Technology, Yongying Fund has a fund that entered the top ten shareholders, holding 3.9273 million shares, which is 4.8% of the circulating shares [2] - The fund, Yongying Advanced Manufacturing Select Mixed Fund A (018124), was established on May 4, 2023, with a latest scale of 4.697 billion CNY and has achieved a return of 72.85% this year [2] - The fund's performance ranks 236 out of 8122 in its category for the year and 99 out of 8056 for the past year, with a cumulative return of 118.62% since inception [2] Group 3 - The fund manager of Yongying Advanced Manufacturing Select Mixed Fund A is Zhang Lu, who has a tenure of 6 years and 125 days [3] - The total asset size of the fund managed by Zhang Lu is 22.921 billion CNY, with the best return during his tenure being 115.11% and the worst being -60.31% [3]

Core Viewpoint - The implementation plan aims to enhance the adaptability of supply and demand for consumer goods, leading to consumption upgrades that drive industrial upgrades, with a goal of achieving a dynamic balance between supply and demand at a higher level by 2027 [1][5]. Group 1: Objectives and Goals - By 2027, the plan targets the formation of three trillion-level consumption sectors and ten hundred-billion-level consumption hotspots, along with the creation of high-quality consumer goods that are culturally rich and globally recognized [6][1]. - By 2030, a high-quality development pattern characterized by positive interaction and mutual promotion between supply and consumption is expected to be established, with a steady increase in the contribution of consumption to economic growth [2][9]. Group 2: Key Strategies - Accelerate the innovation and application of new technologies and models, including the cultivation of flexible manufacturing factories and promoting user participation in design to meet personalized consumer demands [10]. - Expand the supply of distinctive and new products, focusing on green products, rural consumption upgrades, leisure and sports products, health product innovations, and the integration of tourism with wellness services [12]. - Precisely match the needs of different demographic groups by enriching the supply of baby and children's products, enhancing quality student supplies, expanding fashionable "trendy" products, and optimizing products for the elderly [14]. Group 3: New Consumption Scenarios and Environments - Foster new consumption scenarios and business formats, including a matrix for online and offline product launches, promoting "national trends going global," and developing new business models like live e-commerce and instant retail [15]. - Create a favorable development environment by utilizing large-scale equipment updates and trade-in policies for consumer goods, enriching consumer finance products and services, and strengthening regulatory oversight in the consumer sector [17][16].